Brii Biosciences Provides Corporate Update and Reports FY23 Financial Results
Brii Biosciences is going on all in on hepatitis B, hoping potential partners will show interest in the rest of its wide-ranging pipeline.
After trimming its headcount last year in an effort to cut down on operational expenses, VBI Vaccines found another way to improve its financial position with an up to $33 million Brii Biosciences deal that transfers the IP rights to its main vaccine candidate as well as manufacturing digs.
Brii Bio Presents Data Highlighting Progress Towards Achieving HBV Cure
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFN? for the Treatment of Chronic Hepatitis B
Brii Biosciences has stepped in to ease VBI Vaccines’ money problems. The Chinese biotech is handing VBI $15 million to strike a deal that will give it global license to a hepatitis B program—and an ongoing look at its partner’s financial situation.